Advertisement

Antipsychotic Drugs and Interactions: Implications for Criminal and Civil Litigation

  • Michael WelnerEmail author
  • Lewis Opler
Chapter

Abstract

Antipsychotics can be classified into two general types: traditional antipsychotics (also referred to as first-generation antipsychotics or FGAs and as standard neuroleptics) and atypical antipsychotics (also referred to as second-generation antipsychotics or SGAs).

Both traditional and atypical antipsychotics treat positive psychosis symptoms such as hallucinations and delusions by blocking dopamine neurotransmitter receptors [1]. The traditional antipsychotics, however, all cause extrapyramidal motor side effects (EPS), including acute dystonias, drug-induced parkinsonism, and akathisia [1].

Clozapine, the first atypical antipsychotic, was synthesized by scientists attempting to develop a new tricyclic antidepressant. Instead, clozapine turned out to treat positive psychosis symptoms, but, without causing EPS, leading to its being referred to as an atypical antipsychotic.

Keywords

Traditional antipsychotics Atypical antipsychotics Second-generation antipsychotics First-generation antipsychotics 

References

  1. 1.
    Kaplan H, Sadock B (2007) Synopsis of psychiatry: behavioral sciences clinical psychology (10th ed.). Lippincott, Williams and Wilkins, PhiladelphiaGoogle Scholar
  2. 2.
    Stahl S (2001) “Hit-and-run” actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics. J Clin Psychiat 62(9):670–671CrossRefGoogle Scholar
  3. 3.
    Physicians’ Desk Reference. 54th Ed. ©2000 Medical Economics Company, Inc. New JerseyGoogle Scholar
  4. 4.
    Stahl S (2008) Essential psychopharmacology. Cambridge University Press, United KingdomGoogle Scholar
  5. 5.
    Lieberman J, Stroup T, Perkins, D (2006) Textbook of Schizophrenia American Psychiatric Publishing, Inc., VirginiaGoogle Scholar
  6. 6.
    Seeman P (2002) Atypical antipsychotics: Mechanism of action. Can J Psychait 47(1):27–38Google Scholar
  7. 7.
    Wirshing W (2001) Movement disorders associated with neuroleptic treatment. J Clin Psych 62(21):15–18Google Scholar
  8. 8.
    Sethi K (2001) Movement disorders induced by dopamine blocking agents. Semin Neurol 21(1):59–68PubMedCrossRefGoogle Scholar
  9. 9.
    Kaufman D (1990) Clinical neurology for psychiatrists (3 rd ed.). W.B. Saunders Company, PhiladelphiaGoogle Scholar
  10. 10.
    Wallis, L (1998) Textbook of women’s health. Lippincott-Raven, PhiladelphiaGoogle Scholar
  11. 11.
    Mamo D, Sweet R, Mulsant B, et al (2002) Neuroleptic-induced parkinsonism in Alzheimer’s Disease. Psychiat Ann 2(4):249–252Google Scholar
  12. 12.
    Stanilla J, Simpson G (2009) Drugs to treat extrapyramidal side effects. In: Schatzberg A, Nemeroff C. Textbook of Psychopharmacology (4th ed.). American Psychiatric Publishing, Virginia.Google Scholar
  13. 13.
    Hales R, Yudofsky S, Gaddard G (2008) Textbook of psychiatry (5th ed.). The American Psychiatric Publishing, Inc., Virginia:1088.Google Scholar
  14. 14.
    Haddad P, Dursun S (2008) Neurological complications of psychiatric drugs; clinical features and management. Hum Psychopharm Clin 23(1):15–26CrossRefGoogle Scholar
  15. 15.
    Matsumoto R, Pouw B (2000) Correlation between neuroloeptic binding to Singam(1) and Sigma(2) receptors and acute dystonic reactions. Euro J Clin Pharmacol 401(2):155–160CrossRefGoogle Scholar
  16. 16.
    Velickovic M, Benabou R, Brin M (2001) Cervical dystonia pathophysiology and treatment options drugs 6(13):1921–1943CrossRefGoogle Scholar
  17. 17.
    Csernansky J, Schuchart E (2002) Relapse and rehospitalisation rates in patients with Schizophrenia: Effects of second generation antipsychotics. CNS Drugs 16(7):473–484PubMedCrossRefGoogle Scholar
  18. 18.
    Gorman, Jack (1990) The essential guide to psychiatric drugs. St. Martins Press, New YorkGoogle Scholar
  19. 19.
    Holloman L, Marder S (1997) Management of acute extrapyramidal effects induced by antipsychotic drugs. Amer Jourl Health Syst Pharm 54(21):2461–2477Google Scholar
  20. 20.
    Lima A, Soares-Weiser K, Bacaltchuk J, et al (2002) Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 1: CD001950Google Scholar
  21. 21.
    Bernstein J (1984) Clinical psychopharmacology (2nd ed.). John Wright, MassachussettsGoogle Scholar
  22. 22.
    Siris, S (2001). Suicide and Schizophrenia J Psychopharmacol 15(2): 127–135PubMedCrossRefGoogle Scholar
  23. 23.
    Sachdev P (2000) The current status of Tardive Dyskinesia. Aust NZ J of Psychiat 34(3):355–369CrossRefGoogle Scholar
  24. 24.
    Llorca P, Chereau I, Bayle F et al (2002) Tardive dyskinesias and antipsychotics: A Review. Eur J Psychiat 17(3):129–138CrossRefGoogle Scholar
  25. 25.
    Ghadirian A, Annable L, Belanger M et al (1996) A cross-sectional study of Parkinsonism and Tardive Dyskinesia in lithium-treated affective disordered patients. J Clin Psychiat 57(1):22–28Google Scholar
  26. 26.
    Ayd F (2000) Evaluation the interactions between herbal and psychoactive medications. Psychiatric Times 17(12): 45–47Google Scholar
  27. 27.
    Goldberg E (2001) The executive brain. Oxford University Press, New York 94.Google Scholar
  28. 28.
    Physicians Desk Reference 62nd Edition (2008). Thompson Healthcare Inc, Montvale: New JerseyGoogle Scholar
  29. 29.
    Asarnow R (1999) Neurocognitive impairments in Schizophrenia: A piece of the epigenetic puzzle. Eur Child Adoles Psy 8(1):15–18Google Scholar
  30. 30.
    American Psychiatric Association (2000) DSM-IV-TR. Washington, DCGoogle Scholar
  31. 31.
    Knegtering H, Eijck M, Hijsman A (1994) Effects of antidepressants on cognitive functioning of elderly patients. Drug Aging 5(3):192–199CrossRefGoogle Scholar
  32. 32.
    Turrone P, Kapur S, Seeman M et al (2002) Elevation of prolactin levels by atypical antipsychotics. Am J of Psychiat 159(1):133–135CrossRefGoogle Scholar
  33. 33.
    Haddad P, Sharma S (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21(11):911–936PubMedCrossRefGoogle Scholar
  34. 34.
    Allison D, Mentore J, Heo M (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiat 156:1686–1696PubMedGoogle Scholar
  35. 35.
    McIntyre R (2002) Psychotropic drugs and adverse events in the treatment of Bipolar Disorders revisited. J Clin Psychiat 63(3):15–20Google Scholar
  36. 36.
    Haupt D, Newcomer J (2001) Hyperglycemia and antipsycotic medications. J Clin Psych 62(27):15–26Google Scholar
  37. 37.
    Jin H, Meyer J, Jeste D (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14(1):59–64PubMedGoogle Scholar
  38. 38.
    Nourian Z, Mow T, Muftic D, et al (2008) Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of a1-adrenoceptor function. Psychopharmacology 199:15–27PubMedCrossRefGoogle Scholar
  39. 39.
    Jusic N, Lader M (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths. Brit J Psychiat 165:787–791PubMedCrossRefGoogle Scholar
  40. 40.
    Ray W, Meredith S, Thapa, P et al (2001) Antipsychotics and the risk of sudden cardiac death. Arch Gen Psych 58(11):1168–70Google Scholar
  41. 41.
    Markowitz J et al (1995) Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 29:603–609PubMedGoogle Scholar
  42. 42.
    DeVane C, Markowitz J (2001) Avoiding psychotropic drug interactions in the cardiac patient. TEN 3(5):67–71Google Scholar
  43. 43.
    Grohman R, Ruther E, Sassim N et al (1989) Adverse effects of clozapine. Psychopharmacology 99:101–104CrossRefGoogle Scholar
  44. 44.
    Killian J, Kerr K, Lawrence C et al (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354:1841–5CrossRefGoogle Scholar
  45. 45.
    DeVane C, Nemeroff C (2000) Psychotropic drug interactions. Primary Psychiatry 7(10):66Google Scholar
  46. 46.
    Haddad P, Anderson I (2002) Antipsychotic-related QTc prolongation, Torsade de Pointes and sudden death. Drugs 62(11) 1649–71PubMedCrossRefGoogle Scholar
  47. 47.
    Menkes D, Knight J (2002) Cardiotoxicity and prescription of thioridazine in New Zealand. Aust NZ J Psychiat 36(4):492–8CrossRefGoogle Scholar
  48. 48.
    FDA Psychopharmacological Drugs Advisory Committee (2000, July 19). Briefing document for Ziprasidone Hydrochloride.Google Scholar
  49. 49.
    Glassman A, Bigger J (2001) Antipsychotic drugs: prolonged QTc interval, Torsades de Pointes and sudden death. Am J Psychiat, 158(11):1774–82PubMedCrossRefGoogle Scholar
  50. 50.
    Young D (2002) Black-box warning for droperidol surprises pharmacists. Am J Health-Syst Ph 59(6):494, 497, 502–4Google Scholar
  51. 51.
    Smego R, Durack D (1982) The neuroleptic malignant syndrome. Arch Intern Med 142:1183–1185PubMedCrossRefGoogle Scholar
  52. 52.
    Friedman J (1998) Recognition and treatment of the neuroleptic malignant syndrome. Curr Opin Neurol Neu 1(3): 310–311Google Scholar
  53. 53.
    Reeves R, Torres R, Liberto V et al (2002) Atypical Neuroleptic Malignant Syndrome associated with olanzapine. Pharmacotherapy 22(5):641–644PubMedCrossRefGoogle Scholar
  54. 54.
    Sing K, Ramaekers G, Van Harten P (2002) Neuroleptic malignant syand quetiapine. Am J Psychiat 159(1):149–150PubMedCrossRefGoogle Scholar
  55. 55.
    Blum M, Siegel A, Meier R et al (2001) Neuroleptic Malignant-Like Syndrome and Acute Hepatitis during tolcapone and clozapine medication. Eur J Neurol 46(3):158–160CrossRefGoogle Scholar
  56. 56.
    Aboraya A, Schumacher J, Abdalla E, et al (2002) Neuroleptic Malignant Syndrome associated with risperidone and olanzapine in First-Episode Schizophrenia. W VA Med J 98(2):63–65Google Scholar
  57. 57.
    Clayton A (2001) Recognition and assessment of sexual dysfunction associated with Depression. J Clin Psychiat 62(3): 5–9CrossRefGoogle Scholar
  58. 58.
    Compton M, Miller A (2001) Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiat 62(5):362–6CrossRefGoogle Scholar
  59. 59.
    Pacia S, Devinsky O (1994) Clozapine-related seizures: experience with 5,629 patients. Neurology 44(12):2247–2249PubMedGoogle Scholar
  60. 60.
    Jibson M, Tandon R (2001) An overview of antischizophrenic medications. CNS News Special Edition 2001:49–54Google Scholar
  61. 61.
    Weber S (2002) Drug interactions with antidepressants. CNS News February 2002:27–34Google Scholar
  62. 62.
    Mental Fitness Physician Resource Series (2000). Primary Psychiatry 36Google Scholar
  63. 63.
    Modai I, Hirschmann S, Rava A (2000) Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharm 20(3):525–327CrossRefGoogle Scholar
  64. 64.
    DeVane C, Nemeroff C (2000) Quetiapine drug interactions. Primary Psychiatry 7(10)Google Scholar
  65. 65.
    Greenblatt D (2001) Symposium, American Association for Geriatric Psychiatry. Annual meeting, San FranciscoGoogle Scholar
  66. 66.
    Pies R (1983) Geriatric psychopharmacology. Am Fam Physician 28(4):171–176PubMedGoogle Scholar
  67. 67.
    Pollock B (1994) Recent developments in drug metabolism of interest to psychiatrists. Harv Rev Psychiatry 2(4):204–213PubMedCrossRefGoogle Scholar
  68. 68.
    Tsunoda S, Harris R, Mroczkowski P et al (1998) Preliminary evaluation of progestins as inducers of cytochrome activity in post-menopausal women. J Clin Pharmacol 38:1137–1143PubMedGoogle Scholar
  69. 69.
    Tamminga W, Werner J, Oostehuis B et al (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Euro J Clin Pharmacol 55(3):177–184CrossRefGoogle Scholar
  70. 70.
    Volavka J (1999) The effects of clozapine on aggression and substance abuse in Schizophrenic patients. J ClinPsychol 60(12):43–46 1999Google Scholar
  71. 71.
    Perkins v. United States (1915). 228 F 408Google Scholar
  72. 72.
    Lexsee (2001). 73 ALR 3d 195; West GroupGoogle Scholar
  73. 73.
    Teeters v. Commonwelath (1949). 310 Ky 546, 221 SW2d 85Google Scholar
  74. 74.
    Wyngaarden J, Smith L, Bennett J (1992) Cecil textbook of medicine (19th ed.). W.B. Saunders Company, PhiladelphiaGoogle Scholar
  75. 75.
    Meyer P, Bond G, Tunis S (2002) Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. J Clin Psychiat 63(2):108–116CrossRefGoogle Scholar
  76. 76.
    Rosenheck R, Chang S, Choe Y et al (2000) Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psych 61(5):382–386CrossRefGoogle Scholar
  77. 77.
    Takahashi H, Sugita T, Yoshida K, et al (2004) Effect of queiapine in the treatment of panic attacks in patients with Schizophrenia: three case reports. J Nueropsych Clin N16(1):113–5Google Scholar
  78. 78.
    Accardo vs. Cenac (1998). 97 La. 2320; 722 So. 2d 302Google Scholar
  79. 79.
    Barcai vs. Betwee (2002). 98 Haw. 470; 50 P.3d 946Google Scholar
  80. 80.
    Henderson D, Cagliero E, Copeland P, et al (2005) Glucose metabolism in patients with Schizophrenia treated with atypical antipsychotic agents: a frequent sampled intravenous glucose tolerance test and minimal model analysis. Arch General Psychiat 62:19–28CrossRefGoogle Scholar
  81. 81.
    Abelson R (2004, April 24) Texas jury rules against the maker of fen-phen, a diet drug. The New York TimesGoogle Scholar
  82. 82.
    Berenson A (2005, August 20) Jury calls Merck liable in death of man on vioxx. The New York TimesGoogle Scholar
  83. 83.
    Scheller P. (2009). The Largest Pharma Fraud Wistleblower Case in U.S. History. Press ReleaseGoogle Scholar
  84. 84.
    Guinn vs. Astrazeneca (2009) 598 F. Supp. 2d 1239Google Scholar
  85. 85.
    Gillenwater D, McDaniel J (2001) Rational psychopharmacology for patients with HIV infection and AIDS. Psychiat Ann 31(1):28–32Google Scholar
  86. 86.
    Safdar A, Armstrong D (2001) Infectious morbidity in critically ill patients with Cancer. Crit Care Clin 17(3):531–570PubMedCrossRefGoogle Scholar
  87. 87.
    Flanagan R, Dunk L (2008) Haemotological toxicity of drugs used in psychiatry. Hum Psychopharm Clin 23(1):27–41CrossRefGoogle Scholar
  88. 88.
    Welch J, Manschreck T, Redmond D (1994) Clozapine-induced seizures and EEG changes. J Neuropsych Clin N 6(3):250–256Google Scholar
  89. 89.
    Knegtering H, Eijck M, Hijsman A (1994) Effects of antidepressants on cognitive functioning of elderly patients. Drug Aging 5(3):192–199CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.The Forensic PanelNew YorkUSA
  2. 2.New York University School of MedicineNew YorkUSA
  3. 3.The Forensic PanelNew YorkUSA
  4. 4.College of Physicians & SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations